Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) Research & Development (2024 - 2025)

Carlsmed's Research & Development history spans 2 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 67.93% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $20.4 million, changed N/A, while the annual FY2025 figure was $8.7 million, 39.02% down from the prior year.
  • Research & Development reached $2.9 million in Q4 2025 per CARL's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $9.0 million in Q4 2024 to a low of $1.9 million in Q2 2024.